Challenges of harmonising data from UK national health surveys: a case study of attempts to estimate the UK prevalence of asthma by Nwaru, Bright I et al.
Challenges of harmonising data from UK national health surveys:
a case study of attempts to estimate the UK prevalence of
asthma
Nwaru, B. I., Mukherjee, M., Gupta, R. P., Farr, A., Heaven, M., Stoddart, A., ... Sheikh, A. (2015). Challenges of
harmonising data from UK national health surveys: a case study of attempts to estimate the UK prevalence of
asthma. Journal of the Royal Society of Medicine, 108(.), 433-439. DOI: 10.1177/0141076815600909
Published in:
Journal of the Royal Society of Medicine
Document Version:
Early version, also known as pre-print
Queen's University Belfast - Research Portal:
Link to publication record in Queen's University Belfast Research Portal
Publisher rights
© 2015 The Authors
General rights
Copyright for the publications made accessible via the Queen's University Belfast Research Portal is retained by the author(s) and / or other
copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated
with these rights.
Take down policy
The Research Portal is Queen's institutional repository that provides access to Queen's research output. Every effort has been made to
ensure that content in the Research Portal does not infringe any person's rights, or applicable UK laws. If you discover content in the
Research Portal that you believe breaches copyright or violates any law, please contact openaccess@qub.ac.uk.
Download date:15. Feb. 2017
1 
 
Challenges of harmonising data from UK national health surveys: a case study of 
attempts to estimate the UK prevalence of asthma 
 
Bright I Nwaru, Gwyneth Davies, David P Strachan, Michael Shields, Aziz Sheikh, on behalf 
of the Burden and True Cost of Asthma in the UK Research Team 
 
Asthma UK Centre for Applied Research, Centre for Population Health Sciences, The 
University of Edinburgh, Edinburgh, UK Bright I Nwaru research fellow Asthma & Allergy 
Group, Institute of Life Science, College of Medicine, Swansea University, Swansea, UK 
Gwyneth Davies senior lecturer Population Health Research Institute, St George’s University 
of London, London, UK David Strachan professor Centre for Infection and Immunity, School 
of Medicine, Dentistry and Biomedical Sciences, Queen’s University Belfast, Belfast, UK 
Michael Shields professor Asthma UK Centre for Applied Research, Centre for Population 
Health Sciences, The University of Edinburgh, Edinburgh, UK Aziz Sheikh professor 
 
 
Correspondence to: 
 
Aziz Sheikh, MD 
Allergy & Respiratory Research Group, 
Centre or Population Health Sciences,  
The University of Edinburgh,  
Teviot Place, 
Edinburgh EH8 9AG, UK 
aziz.sheikh@ed.ac.uk 
 
 
 
 
Key words 
asthma, health surveys, policymakers, prevalence, United Kingdom 
 
 
 
Word count: 1997 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2 
 
Considerable resources are invested in population-based health surveys in order to provide 
estimates of disease prevalence and severity, but our recent attempt to estimate the UK 
prevalence of asthma from these health surveys identified major differences in the questions 
used by UK nations thus making it very challenging to generate comprehensive UK-wide 
estimates from these national datasets.   
 
The United Kingdom (UK) ranks among the highest in the world in the prevalence, 
healthcare utilisation, and mortality from asthma.1-4 Asthma therefore rightly represents a 
major concern for policymakers.5-7 There is however no comprehensive overall picture of the 
numbers of people with asthma or indeed the associated morbidity and costs, this reflecting 
the fact that previous efforts have drawn on isolated or limited number of datasets, which 
have focused predominantly on a particular age group and/or UK nation.4,8-14 We were 
commissioned by Asthma UK to investigate the epidemiology, healthcare utilisation and 
costs of asthma care for the UK as a whole and its member nations, i.e. England, Northern 
Ireland, Scotland, and Wales. Fundamental to this work was our plan to interrogate serial, 
population-based national health surveys and routine health data in order to estimate the 
prevalence of asthma. Similar repeat surveys have proven useful in appreciating the burden 
of asthma across different world regions.15-20 Here we describe the challenges we 
encountered in interrogating and harmonising data from these serial population-based health 
surveys in order to derive UK-wide estimates on the most basic of these outcomes, namely 
the prevalence of asthma. We conclude by proposing possible solutions that will help ensure 
that the significant resources invested in these national surveys generate comparable data 
on asthma and possibly other disease areas. 
 
National health surveys 
Each UK nation undertakes serial population-based cross-sectional surveys of a randomly 
selected sample of people from the general population, which collect information on health 
and diseases, utilisation of healthcare and social services, and on factors that affect health. 
The data from these surveys are extensively used by policymakers and service planners for 
organising healthcare and to an extent social care services; these have also served as 
important sources of data for researchers in investigating population health and its 
determinants. The surveys are implemented by respective national social and health service 
institutions and the data are archived by the UK Data Archive (http://www.data-
archive.ac.uk/). We utilised the surveys described below for the period 2001-2012: 
 
Health Survey for England (HSE) 
The HSE began in 1991 and is carried out annually. It includes core sets of questions and 
measurements on various disease conditions; each year’s survey however also focuses on a 
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particular disease condition or a specific population group. Participants are selected by 
means of a stratified random probability sample of households. Since 2001, all age groups, 
from infants of six weeks and older, have been sampled. The respiratory module of the 
survey covers symptoms, diagnoses and treatment for asthma and chronic obstructive 
pulmonary disease (COPD); over the current project period, the respiratory module was 
included in 2001, 2002, 2004, and 2010 surveys.  
 
Northern Ireland Health and Social Wellbeing Survey (NIHSWS) and Northern Ireland 
Health Survey (NIHS) 
NIHSWS was carried out in 1997, 2001, and 2005/2006, but was replaced by NIHS in 
2010/2011 which now runs annually, both surveys having similar designs and topics 
covered. Respondents were randomly selected adults, ≥16 years; parents or guardians 
responded on behalf of children. We used the 2001 and 2005/2006 NIHSWS surveys and 
the 2010/2011 NIHS. 
 
Scottish Health Survey (SHeS) 
SHeS began in 1995; repeated in 1998, 2003 and 2008, and has been undertaken annually 
since 2008. Representative sample of households and participants across Scotland are 
selected using cluster sampling. Each survey involves two stages of interviews: a personal 
interview undertaken by trained interviewers and a nurse visit in a sample of the participants 
that includes an interview and anthropometric and biological measurements. For the current 
project, asthma-related questions were included in 2003, 2008, 2010, and 2012 surveys.  
 
Welsh Health Survey (WHS) 
The current WHS began in 2003; it replaced two previous serial surveys: the WHS 
conducted in 1995 and 1998 and the Health in Wales Survey conducted five times between 
1985 and 1996. Since its, the WHS has been carried out annually and constitutes an un-
clustered sample of adults and children selected from strata of local authorities. The content 
of the WHS has been largely the same since it was established in 2003, with the inclusion of 
questions on the health of children in 2007. For the current project, asthma-related questions 
were included in 2003, 2007, 2008, 2010, 2011, and 2012 surveys.  
 
Asthma questions across national surveys 
Identical questions were asked in the HSE and the SHeS about wheezing symptoms, but no 
wheezing symptom related question was asked in the surveys from Wales and Northern 
Ireland (Table 1). In the English, Scottish, and Northern Ireland surveys, the question about 
clinician-diagnosed asthma was similar, but was not asked in the Welsh survey. An 
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additional question on asthma symptom during the past 12 months was asked in the English 
survey while in the Northern Ireland surveys the question was on asthma attacks in the past 
12 months. The English and Northern Ireland surveys asked similar questions on use of 
asthma medication or treatment for asthma; i.e. on whether the respondent has used any 
asthma medication during the past 12 months. In the Scottish survey, the question was on 
whether the respondent has received treatment or advice for asthma from a list of health 
professionals in the past 12 months. In the Welsh survey, the question was on whether the 
respondent was currently being treated for asthma, and this was the only asthma question 
asked in the Welsh survey. 
 
Defining asthma, harmonising definitions, and comparing estimates of asthma 
prevalence across national surveys 
By utilising the asthma questions asked across the surveys, we aimed to define: (1) reported 
lifetime and current symptoms suggestive of asthma; (2) reported lifetime and current 
clinician-diagnosed asthma; and (3) reported current treated clinician-diagnosed asthma. 
Our goal was to harmonise these asthma definitions across national surveys in order to 
derive both national-specific and UK-wide estimates of asthma prevalence. However, as 
shown in Table 1, formulating working definitions of lifetime and current symptoms 
suggestive of asthma were only possible within the English and Scottish surveys, while 
formulating working definitions of lifetime and current clinician-diagnosed asthma were 
possible within the English, Northern Ireland, and Scottish surveys. Developing a working 
definition of current treated clinician-diagnosed asthma was possible within all the national 
surveys, but the definition used within the Welsh survey was different from that used by the 
other surveys as only one question (on whether the respondent is currently being treated for 
asthma) was asked in that survey, whereas the combination of questions in the other 
surveys ensured that those receiving medication or being treated for asthma also reported 
being diagnosed as having asthma. Although it is unlikely that those that reported being 
currently treated for asthma would actually have no asthma, the conditioning of the treatment 
part of the definition on reported clinician-diagnosed asthma ensured a uniformity of 
definition across surveys. This conditioning is important given that some asthma medications 
may be used for other conditions. Overall, apart from the definition of current treated asthma, 
it was impossible to harmonise other working definitions of asthma across national surveys 
because the questions related to these definitions were not asked across all surveys. 
 
To compare the estimates of asthma prevalence as derived from the above definitions 
between each nation, we calculated the age-standardised gender-specific prevalence 
estimates in adults (≥16 years) where data were available based on the 2010/2011 national 
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surveys (which was the latest survey in all nations during the project period, except for 
Wales) using the European Standard Population 2013 version as the reference population 
(Table 2). The prevalence of all outcomes was highest in England across gender compared 
to other countries, except for the prevalence of current treated clinician-diagnosed asthma 
which was highest in Wales (Table 2). While the differences between nations regarding 
lifetime clinician-diagnosed asthma appeared reasonable, the differences regarding current 
clinician-diagnosed asthma and current treated clinician-diagnosed asthma were large: for 
current physician-diagnosed asthma, up to 49% difference between England and Scotland 
and 142% between England and Northern Ireland in men, and up to 54% difference between 
England and Scotland and 166% between England and Northern Ireland in women; for 
current treated clinician-diagnosed asthma, up to 70% difference between Wales and 
Scotland in men and up to 67% difference between Wales and Scotland in women. It is thus 
unclear whether these are real differences or as a result of the specific ways these questions 
have been framed in each nation. For instance, the question on clinician-diagnosed asthma 
referred to a “doctor or nurse” in England, while it referred only to a “doctor” in Scotland and 
Northern Ireland. Furthermore, the question combined to define clinician-diagnosed asthma 
focused on wheezing symptoms in England and Scotland, but asked for asthma attacks in 
Northern Ireland. It is unclear how intuitive a question on asthma attacks appears to 
participants. The question on treated clinician-diagnosed asthma in Wales was only a single 
question asking whether the participant is currently receiving treatment for asthma. 
 
Concluding remarks and suggestions for future work 
Serial health surveys are potential useful sources for estimating the prevalence of self-
reported symptoms of a number of health conditions. In the field of asthma research, the 
International Study of Asthma and Allergy in Childhood (ISAAC) is an important example of a 
serial research study, which has generated comparable longitudinal data on the 
epidemiology and risk factors for asthma and allergy across different world regions.15 
However, our attempt to interrogate and work on UK surveys has shown that deriving 
prevalence estimates across UK nations can prove very challenging as a result of the 
different ways in which questions on asthma have been asked across national surveys. 
These differences limited the possibility of meaningful harmonisation and formulation of 
common working definitions of asthma across the four nations and thus precluded our 
overall goal of deriving reliable UK-wide and nation-specific estimates of reported prevalence 
of asthma symptom, clinician-diagnosed asthma, and clinician-diagnosed current asthma 
requiring treatment. 
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We do not know how widespread the above challenges are with regards to other disease 
conditions, but we believe that a fundamental step in mitigating these is that there should be 
greater dialogue cooperation between institutions responsible for organising the surveys 
across the UK nations. Such closer working ties will ensure that consideration is given to 
ensuring that the same questions are asked across national surveys, which will then allow 
more comparability and harmonisation of the definitions of asthma across nations and, 
accordingly will facilitate derivation of a UK-wide and comparable national-specific estimates 
of the prevalence of asthma (and possibly other long-term conditions). In addition, such 
cooperation could also facilitate the planning and conduct of the surveys during the same 
year and season across the four nations, where possible, which will ensure better 
comparison of the annual and seasonal variations in the prevalence of asthma across the 
UK.  
 
Drawing on our ongoing experience of using these surveys, we have identified a core set of 
asthma questions for defining different measures of asthma prevalence (Box 1), which we 
suggest should be considered in future national health surveys. While there may be a need 
to retain the original questions that have been asked in each national survey in order to 
maintain historicity and time-trend analysis, we suggest that these core set of questions be 
integrated and included in future surveys, which we believe will enable direct comparison 
across nations and derivation of UK-wide estimates. These core questions are comparable 
to the questions from the World Health Survey,17,18 ISSAC,15,19 and the European 
Community Respiratory Health Survey (ECHRS),20 but some slight differences remain, 
particularly the inclusion of a “nurse” in Question C; this is important as nurses may 
diagnose asthma in the UK. Question D is an additional question not appearing in World 
Health Survey, ISAAC, and ECHRS, but we believe it is a good complement to Questions A 
and B when combined with Question C in deriving current clinician-diagnosed asthma. 
ISAAC does not have a question on asthma diagnosis and medication or treatment, but 
World Health Survey and ECHRS do.  Finally, similar analyses need to be considered in 
relation to the questions in other disease areas to ascertain how widespread an issue this 
failure to harmonise questions is. 
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Box 1 Core set of asthma questions in defining different asthma prevalence measures 
 
 
 
 
 
 
 
 
 
 
 
 
 
Key messages 
• Serial population health surveys are useful data sources for generating estimates 
about the prevalence of asthma and many other long-term conditions 
• Our attempt to harmonise asthma questions from serial national surveys across the 
UK in order to derive UK-wide and comparable national-specific prevalence 
estimates of asthma proved very challenging because of the variations in the 
availability and framing of relevant asthma questions across the national surveys 
• We have identified a core set of asthma questions that we suggest should be used 
across all four nations in future surveys 
• Future planning of these surveys should involve closer cooperation across the UK 
nations in order to allow for more comparability and harmonisation of survey 
questions and to ensure the respiratory modules are included in the same years; and 
consideration needs to be given to undertaking similar work in other disease areas. 
 
 
 
 
 
 
 
Core set of questions to include in future surveys 
 
A. Have you ever had wheezing or whistling in the chest at any time, either now or in the past? 
B. Have you had this wheezing or whistling in the chest in the last 12 months? 
C. Did a doctor or nurse ever tell you that you had asthma at any time, either now or in the past? 
D. Have you had any symptoms of asthma in the last 12 months? 
E. Have you received any treatment for your asthma/wheezing/whistling in the last 12 months? 
 
Defining different asthma prevalence measures based on above questions 
 
Prevalence of lifetime symptoms suggestive of asthma: (question A) 
 
Prevalence of current symptoms suggestive of asthma: (combination of questions A and B) 
 
Prevalence of lifetime clinician-diagnosed asthma: (question C) 
 
Prevalence of current clinician-diagnosed asthma: (combination of [either question A or C] and D) 
 
Prevalence of current treated clinician-diagnosed asthma: (combination of [either question A or C] and E) 
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Table 1 Asthma questions asked in respective national surveys in the UK 
Nation, Survey and 
survey years studied 
Different asthma definitions and applicable survey questions 
 
Lifetime 
symptomatic 
asthma 
Lifetime clinician-
diagnosed asthma 
Current symptomatic 
asthma 
 
Current clinician-diagnosed 
asthma 
Current treated clinician-
diagnosed asthma 
England, Health Survey 
for England 2001, 2002, 
2004, 2010 
Have you ever had 
wheezing or whistling 
in the chest at any 
time, either now, or 
in the past? 
Did a doctor or 
nurse ever tell you 
that you had 
asthma? 
Have you had wheezing 
or whistling in the chest 
in the last 12 months? 
Did a doctor or nurse ever tell you 
that you had asthma? AND (Have 
you had any symptoms of asthma in 
the last 12 months, or are they 
controlled by medication? OR Have 
you had wheezing or whistling in the 
chest in the last 12 months?) 
 
Did a doctor or nurse ever tell you 
that you had asthma? AND Over the 
last 12 months, have you used an 
inhaler, puffer or nebuliser prescribed 
by a doctor to treat your asthma, 
wheezing or whistling, or difficulty in 
breathing? 
 
Northern Ireland, 
Northern Ireland Health 
and Social Wellbeing 
Survey and the Northern 
Ireland Health Survey 
2001, 2005/2006, 
2010/2011 
 Have you ever 
been told by a 
doctor that you had 
any of the 
conditions on this 
card? (asthma) 
 Have you ever been told by a doctor 
that you had any of the conditions on 
this card? (asthma) AND (Have you 
had an asthma attack during the past 
12 months? OR Do you currently 
suffer from any of the following 
conditions? (asthma)) 
Have you ever been told by a doctor 
that you had any of the conditions on 
this card? (asthma) AND (Have you 
had an asthma attack during the past 
12 months? OR (Do you currently 
suffer from any of the following 
conditions? (asthma)) AND In the 
past 12 months, have you taken 
medication for asthma such as 
inhalers, nebulizers, pills, liquids or 
injections?) 
 
Scotland, Scottish 
Health Survey 2003, 
2008, 2010 
Have you ever had 
wheezing or whistling 
in the chest at any 
time, either now or in 
the past? 
 
Did a doctor ever 
tell you that you 
had asthma? 
Have you ever had 
wheezing or whistling in 
the chest in the last 12 
months? 
Did a doctor ever tell you that you 
had asthma? AND Have you ever 
had wheezing or whistling in the 
chest in the last 12 months? 
Did a doctor ever tell you that you 
had asthma? AND Have you 
received any treatment or advice for 
your (asthma/wheezing or whistling) 
from any of the people on this card 
last 12 months? 
 
Wales, Welsh Health 
Survey 2003, 2007, 
2008, 2010, 2011, 2012 
 
    Are you currently being treated for 
any of these? (asthma) 
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Table 2 Age-standardised1 prevalence of asthma in adults (≥16 years) per 1000 population based on the different asthma definitions 
given in Table 1: estimates are based on the 2010/2011 survey used in the project from each UK nation 
Nation and survey 
year 
 
N2 
Lifetime symptomatic 
asthma 
n3 (Prevalence, 95% CI)4 
Lifetime clinician-
diagnosed asthma 
n3 (Prevalence, 95% CI)4 
Current symptomatic 
asthma 
n3 (Prevalence, 95% CI)4 
Current clinician-
diagnosed asthma 
n3 (Prevalence, 95% CI)4 
Current treated clinician-
diagnosed asthma 
n3 (Prevalence, 95% CI)4 
 
MEN 
England, 2010 3702 
 
1377 (332, 315-350) 670 (155, 143-167) 768 (189, 175-202) 409 (97, 87-107) 345 (83, 74-92) 
Northern Ireland, 
2010/2011  
1684  180 (114, 97-131)  58 (40, 29-50)  
5 
Scotland, 2010 1014 279 (248, 218-278) 151 (132, 110-154) 166 (149, 125-171) 74 (65, 50-81) 61 (54, 40-68) 
Wales, 2010 7041     669 (92, 85-100) 
 
WOMEN 
England, 2010 4718 
 
2718 (311, 294-328) 736 (169, 157-181) 779 (181, 168-194) 506 (117, 107-127) 447 (104, 94-113) 
Northern Ireland, 
2010/2011  
2401  278 (122, 108-137)  97 (44, 35-53)  
5 
Scotland, 2010 1374 317 (254, 226-282) 194 (144, 110-154) 360 (156, 134-178) 95 (76, 61-92) 90 (73, 58-88) 
Wales, 2010 8118     946 (122, 114-130) 
1Standardisation was undertaken using the European Standard Population 2013 revision 
2Unweighted bases 
3Weighted events 
4All confidence intervals undertaken using the Poisson Approximation 
**Shaded cells means no data available; although questions on treated asthma was asked in the surveys from Northern Ireland, data were lacking for these 
variables 
